Menopause treatment coverage expands

Summary#

H-8587, “An Act Relating to Insurance—Accident and Sickness Insurance Policies,” would amend four Rhode Island insurance laws; it does not create a new agency or benefit program. Its stated goal is to require coverage for medically necessary treatments for symptoms of perimenopause and menopause. The bill is introduced and has been recommended for further study, so it is not law.

  • Insurers covered by the amended laws would have to cover medically necessary hormone therapy under individual or group policies delivered, issued, or renewed in Rhode Island on or after January 1, 2027.
  • For three of the four laws, the bill says coverage must include at least one FDA-approved hormonal and non-hormonal treatment, plus at least one hormone replacement therapy option in each of four forms: oral, transdermal (through the skin), topical, and vaginal.
  • The fourth law, for health maintenance organizations, repeats the general coverage requirement but does not include that list of minimum treatment options.
  • The bill would take effect upon passage. It does not set a separate start date for the law itself.

What it means for you#

  • People with affected health insurance: If your policy is covered by one of the amended laws, the insurer would have to provide the required coverage. The bill does not say that every treatment a patient or clinician prefers must be covered.
  • Insurers: They would have to provide coverage under the conditions above. The bill does not create a process for patients to apply for coverage or appeal a denial.
  • People seeking treatment: The bill text requires treatment to be medically necessary, but does not define that term. The explanatory note says treatment must be recommended by a qualified provider licensed, accredited, or certified in Rhode Island and proven safe and effective; those conditions are not stated in the operative bill text. The text does specify FDA approval for the minimum treatments listed in three of the four laws.
  • Current law: The materials do not include the existing text of the four laws, so what coverage is already required—and exactly how much this would change it—could not be verified.

Money#

No cost information is in the available material.

  • The bill requires coverage but gives no estimate of added costs to insurers, policyholders, or the state.
  • It does not set fees, fines, or a specific public funding amount.

What is unclear#

  • Which policies are covered beyond the individual and group policies described in the bill, and how the requirements interact with other coverage rules, are not explained.
  • “Medically necessary” is not defined, and the bill does not set coverage review, denial, or appeal rules.
  • The explanatory note adds provider and safety conditions that do not appear in the operative text.
  • The coverage minimum is spelled out in three amended laws but omitted from the health maintenance organization section, which repeats the general requirement.
  • The bill does not explain how the required coverage would be implemented or monitored.

Case for#

  • A possible argument for the bill is that people seeking treatment for perimenopause or menopause symptoms would have a legal coverage requirement rather than relying only on what their policy already covers.
  • The minimum treatment options in three sections could give patients access to more than one type of treatment and several ways to take hormone replacement therapy.
  • Applying the requirement to both individual and group policies could make the coverage rule more consistent across those policies.

Case against#

  • One concern is that the bill does not define medical necessity or set review and appeal rules, leaving important coverage decisions unresolved.
  • The health maintenance organization section lacks the specific minimum treatment options included in the other three sections, creating uncertainty about what coverage it requires.
  • The explanatory note describes provider and safety conditions that the operative text does not include, which could lead to disagreement about the intended rule.
  • The bill gives no cost estimate, so the effect on insurers and policyholders cannot be assessed from the available material.